US Stock Market Move | Lilly (LLY.US) rose more than 2%, Zepbound has much better weight loss effects than Wegovy.

On Monday, shares of Eli Lilly (LLY.US) rose over 2% to $752.61. In terms of news, on May 11th local time, Lilly announced that the comparative trial data showed that its weight loss drug Zepbound had a weight loss effect nearly 50% higher than its competitor Novo Nordisk's similar drug Wegovy. The study published in the New England Journal of Medicine showed that patients using Zepbound had an average weight loss of 50 pounds (approximately 22.8 kilograms) after 72 weeks of treatment, while patients using Wegovy lost about 33 pounds (approximately 15 kilograms).